3,732 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Clarus Wealth Advisors

Clarus Wealth Advisors acquired a new position in shares of Pfizer Inc. (NYSE:PFEGet Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,732 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Baltimore Washington Financial Advisors Inc. bought a new position in Pfizer during the fourth quarter worth about $290,000. PYA Waltman Capital LLC bought a new position in Pfizer during the fourth quarter worth about $31,000. Econ Financial Services Corp bought a new position in Pfizer during the fourth quarter worth about $31,000. Rinkey Investments bought a new position in Pfizer during the fourth quarter worth about $32,000. Finally, Bivin & Associates Inc. bought a new position in Pfizer during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 66.50% of the company’s stock.

In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares in the company, valued at $1,907,300. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,126 shares of company stock worth $2,075,003. 0.05% of the stock is owned by insiders.

PFE has been the subject of a number of analyst reports. Barclays set a $52.00 price objective on shares of Pfizer in a research report on Tuesday, May 17th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. SVB Leerink initiated coverage on shares of Pfizer in a research report on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research report on Tuesday, May 3rd. Finally, Citigroup raised their price objective on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.26.

PFE stock opened at $49.07 on Thursday. The company has a market capitalization of $275.33 billion, a PE ratio of 11.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.76. Pfizer Inc. has a one year low of $38.82 and a one year high of $61.71. The company’s 50 day moving average price is $50.57 and its two-hundred day moving average price is $52.22. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. During the same period in the previous year, the firm earned $0.93 earnings per share. The firm’s quarterly revenue was up 76.8% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 6.61 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend was Thursday, May 12th. Pfizer’s payout ratio is 36.70%.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.